Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities and Shareholders Equity (2016 - 2025)

Agios Pharmaceuticals' Liabilities and Shareholders Equity history spans 14 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 22.0% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $5.7 billion, up 12.44%, while the annual FY2025 figure was $1.3 billion, 22.0% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.3 billion in Q4 2025 per AGIO's latest filing, down from $1.4 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.5 billion in Q1 2021 to a low of $773.1 million in Q2 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $1.4 billion, with a median of $1.3 billion recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 211.16% in 2021, then tumbled 46.32% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.4 billion in 2021, then decreased by 13.84% to $1.2 billion in 2022, then decreased by 24.35% to $937.1 million in 2023, then soared by 77.48% to $1.7 billion in 2024, then dropped by 22.0% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Liabilities and Shareholders Equity are $1.3 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.5 billion (Q2 2025).